In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Knowable Magazine reports on breakthroughs in HIV treatment; engineered antibodies show promise for long-term control, ...

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people ...

Sheen appeared on the “Today” show in 2015 and revealed his HIV status, saying doctors had detected the virus four years ...

Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...

The Ghana AIDS Commission (GAC) has expressed concern that poor condom usage among young people, particularly adolescent ...

Nurse practitioners discuss evidence-based cancer screening and risk-reduction strategies that primary care clinicians can implement for patients with HIV.

"Gilead’s HIV ART combo deemed non-inferior in second Phase III trial" was originally created and published by Clinical ...

Paper in @jclinicalinvest (bit.ly/497z6jo) by @HopkinsMedicine @JHUMed_ID finds patient living w/ #HIV has dramatic drop in ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are ...

For several years, pre-exposure prophylaxis against HIV (PrEP) has been a major success in preventing new cases. However, ...